Announcements Trials

Browse Landscape

Phase

Status

Recruiting 1 Completed 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Vomiting 1 Recurrence 1 Pancreatic Neoplasms 1 Nausea 1 Multiple Myeloma 1 Medulloblastoma 1 Leukemia, Myeloid, Acute 1 Leukemia, Lymphocytic, Chronic, B-Cell 1 Leukemia, Large Granular Lymphocytic 1 Ependymoma 1

Interventions

lutetium Lu 177 dotatate 2 Temozolomide 2 ONC206 2 Etoposide 2 Cyclophosphamide 2 Bevacizumab 2 olaparib 1 neratinib 1 ibrutinib 1 fenofibric acid 1 etoposide phosphate 1 brigatinib 1 Watchful Waiting 1 Thalidomide 1 Restraint, Physical 1 Radiotherapy 1 Radiation 1 Magnetic Resonance Spectroscopy 1 Linear Energy Transfer 1 Irinotecan 1 Elasticity Imaging Techniques 1 Cytarabine 1 Celecoxib 1 Automobiles 1 1-methyltryptophan 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × Ependymoma × Thalidomide × Clear all

NCT01356290 2026-02-23

MEMMAT

Medical University of Vienna

Phase 2 Recruiting

Ependymoma, Medulloblastoma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡